Brian Walters-led investor group completed the acquisition of the antibody discovery business of EQT-backed Aldevron, a biotechnology firm. Brian Walters is the current president of the business unit and longtime employee of Aldevron. Financial terms were not disclosed. "This announcement is a positive outcome for both Aldevron and GENOVAC. This transaction will allow Aldevron to focus more resources on developing the highest quality plasmid DNA, mRNA, custom enzymes and proteins for the rapidly growing gene and cell therapy fields, as well as vaccine development. This added focus is especially important as we support key clients in their efforts to develop safe and effective vaccines for Covid-19," Kevin Ballinger, Aldevron CEO.